Showing 2714 results
-
Press Release /High-dose, once-daily Enerzair® Breezhaler® [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks1 Once-daily Enerzair…
-
Press Release /By 2020, over 1.5 million people in the US are likely to have wet AMD, the leading cause of blindness in industrialized countries Filing is based on Phase III data from the HAWK and HARRIER…
-
Press Release /Ph 3 STR1VE data show prolonged event-free survival, early and rapid increases in CHOP-INTEND and significant milestone achievement in SMA Type 1, consistent with START trial First-in-human…
-
Ad-hoc Releases /La transformation en une société axée sur les médicaments a continué avec le spin-off d'Alcon; les commentaires ci-après ne concernent que les activités poursuivies[2] Chiffre d'affaires net des…
-
Ad-hoc Releases /Die Transformation zu einem fokussierten Arzneimittelunternehmen schreitet mit der Abspaltung von Alcon voran; die folgenden Angaben beziehen sich auf die fortzuführenden Geschäftsbereiche[2]…
-
Ad-hoc Releases /Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2] Continuing operations net sales up 7% (cc[1], +2% USD) driven by…
-
Press Release /Novartis leads the way at AAN with 52 abstracts, showcasing its broad portfolio of transformative medicines and innovative solutions for people living with spinal muscular atrophy (SMA), multiple…
-
Press Release /Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors Per licence agreement,…
-
Press Release /Interim data reported for the first time from STRONG in SMA Type 2 showed rapid motor function gains and milestone achievements with intrathecal Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101…
-
Press Release /After long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average Separate study…